← 治験一覧に戻る
進行子宮内膜がん患者におけるレンバチニブとペムブロリズマブの併用と医師選択治療の比較（MK-3475-775/E7080-G000-309 Merck Standard Convention [KEYNOTE-775]）
基本情報
- NCT ID
- NCT03517449
- ステータス
- 完了
- 試験のフェーズ
- 第3相
- 試験タイプ
- 介入
- 目標被験者数
- 827
- 治験依頼者名
- Eisai Inc.
概要
This is a study of pembrolizumab (MK-3475, KEYTRUDA®) in combination with lenvatinib (E7080) versus treatment of physician's choice (doxorubicin or paclitaxel) for the treatment of advanced endometrial cancer. Participants will be randomly assigned to receive either pembrolizumab and lenvatinib or treatment of physician's choice. The primary study hypothesis is that pembrolizumab in combination with lenvatinib prolongs progression free survival (PFS) and overall survival (OS) when compared to treatment of physician's choice.
対象疾患
Endometrial Neoplasms
介入
Pembrolizumab(DRUG)
Lenvatinib(DRUG)
Paclitaxel(DRUG)
Doxorubicin(DRUG)